Skip to main content

Special Issue May 2012, Vol 5, No 3

In 2010, there were an estimated 68,130 new melanoma cases in the United States, of which approximately 2% to 5% presented with metastatic disease. Read More ›

The leading cause of cancer death among men and women is lung cancer. According to the American Cancer Society (ACS), more people die of lung cancer than of breast, colon, and prostate cancers combined. Because this deadly disease affects so many Americans, lets delve into these lung cancer–related statistics.

Lung cancer (both small cell and non–small cell) is the second most common cancer in both men (after prostate cancer) and women (after breast cancer).

Approximately 14% of all new cancers are lung cancers.

Read More ›

The link between cancer and thrombosis has been known for many years. Recently this connection has come to the forefront with increased recognition by healthcare providers and mandates by governing bodies. The results of a thromboembolic event can be catastrophic in a patient with cancer. Read More ›


Use of Bone-Modifying Agents in Oncology Patients

With advances in the diagnosis and treatment of cancer, the estimated 5-year survival rate for cancer patients has significantly improved to approximately 67%.1 The most common malignancies in men and women in the United States—breast and prostate cancers—have 2 of the highest 5-year survival rates reported, at 90% and 99%, respectively.1 As oncology patients are living longer, bone health has become a pertinent issue in the treatment of both metastatic and nonmetastatic oncology patients.2

Read More ›

Myeloproliferative neoplasms (MPNs) are somewhat rare chronic hematologic malignancies. There are no known cures, but the disease itself is treatable. Read More ›

Page 2 of 2